{"organizations": [], "uuid": "9275ec45397a4cffec119f1c714928638e9b8776", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180402.html", "section_title": "Archive News &amp; Video for Monday, 02 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-dar-bioscience-says-intends-to-com/brief-dar-bioscience-says-intends-to-communicate-with-u-s-fda-in-mid-2018-regarding-phase-2b-study-of-topical-sildenafil-idUSASC09UJC", "country": "US", "domain_rank": 408, "title": "BRIEF-Daré Bioscience Says Intends To Communicate With U.S. FDA In Mid-2018 Regarding Phase 2b Study Of Topical Sildenafil", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.862, "site_type": "news", "published": "2018-04-03T04:20:00.000+03:00", "replies_count": 0, "uuid": "9275ec45397a4cffec119f1c714928638e9b8776"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-dar-bioscience-says-intends-to-com/brief-dar-bioscience-says-intends-to-communicate-with-u-s-fda-in-mid-2018-regarding-phase-2b-study-of-topical-sildenafil-idUSASC09UJC", "ord_in_thread": 0, "title": "BRIEF-Daré Bioscience Says Intends To Communicate With U.S. FDA In Mid-2018 Regarding Phase 2b Study Of Topical Sildenafil", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "dare bioscience inc", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 2 (Reuters) - Dare Bioscience Inc:\n* DARÉ BIOSCIENCE, INC. REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE\n* DARE BIOSCIENCE - INTENDS TO COMMUNICATE WITH U.S. FDA IN MID-2018 REGARDING PHASE 2B STUDY OF TOPICAL SILDENAFIL\n* ANTICIPATES COMMENCING A PHASE 2B STUDY OF TOPICAL SILDENAFIL IN Q4 OF 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-03T04:20:00.000+03:00", "crawled": "2018-04-03T16:07:51.001+03:00", "highlightTitle": ""}